Evidence Summary
- Evidence Level
- Preliminary
- Mechanism
- Enrollment: Estimated, Sponsor Type: Other, Unknown / General
- Safety
- Cholinergic side effects (GI cramping, diarrhea, salivation, sweating, bradycardia). Avoid in asthma, mechanical obstruction. Overdose risk cholinergic crisis.
- Dosing
- 30–60 mg TID (sometimes 30 mg); titrate; study durations often 4–8 weeks for hemodynamic assessment.
Crossover RCT + review supports hemodynamic benefit, esp hyperadrenergic POTS. 30-60mg TID. Cholinergic SE dose-limiting. Reasonable targeted option.
Clinical Trials
1 trial(s) registered
| NCT ID | Title | Phase | Status |
|---|---|---|---|
| NCT06366724 | LIFT: Life Improvement Trial | Phase 2 | Recruiting |
Key Studies / References
- See linked studies